{"id":"oral-alprazolam","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Drowsiness"},{"rate":"15-30","effect":"Dizziness"},{"rate":"10-20","effect":"Cognitive impairment"},{"rate":null,"effect":"Dependence/withdrawal risk"},{"rate":"5-15","effect":"Ataxia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alprazolam is a benzodiazepine that binds to GABA-A receptors in the central nervous system, potentiating the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx into neurons, hyperpolarizing the cell membrane and reducing the likelihood of neuronal firing. The result is decreased anxiety, muscle relaxation, and sedation.","oneSentence":"Alprazolam enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:37.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Anxiety associated with depression"}]},"trialDetails":[{"nctId":"NCT05006079","phase":"PHASE2","title":"Opioid/Benzodiazepine Polydrug Abuse: Aim 3","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2024-03-13","conditions":"Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse","enrollment":24},{"nctId":"NCT06874452","phase":"PHASE4","title":"An Extension Test of Whether to Use Oral Anti-anxiety Drugs (XANAX) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-03-25","conditions":"Ophthalmology, Cataract Surgery Anesthesia, Oral Anxiolytic","enrollment":250},{"nctId":"NCT06826417","phase":"NA","title":"Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-01-02","conditions":"Oral Anxiolytic, Phacoemulsification, Cataract Surgery","enrollment":400},{"nctId":"NCT07154147","phase":"PHASE4","title":"Oral vs IV Sedation for Cataract Surgery in Older Adults","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-08-12","conditions":"Cataract Surgery, Sedation, Cognition Function","enrollment":20},{"nctId":"NCT06757140","phase":"PHASE1, PHASE2","title":"Opioid Drug Interaction Study","status":"RECRUITING","sponsor":"Shanna Babalonis, PhD","startDate":"2025-04-01","conditions":"Drug Interactions, Drug Kinetics","enrollment":25},{"nctId":"NCT05602818","phase":"PHASE1","title":"A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-11-15","conditions":"Healthy Volunteers","enrollment":100},{"nctId":"NCT03509285","phase":"PHASE1","title":"A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2017-03-08","conditions":"Healthy Volunteer","enrollment":53},{"nctId":"NCT06097676","phase":"PHASE4","title":"An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2021-09-28","conditions":"Abuse Potential","enrollment":86},{"nctId":"NCT05626439","phase":"PHASE1","title":"A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-12-28","conditions":"Healthy Participants","enrollment":21},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04970342","phase":"PHASE1","title":"Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim","status":"COMPLETED","sponsor":"Timothy L. Brown","startDate":"2021-07-16","conditions":"Driving Behavior, Driving Under the Influence","enrollment":13},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03635437","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes","status":"COMPLETED","sponsor":"Per-Ola Carlsson","startDate":"2018-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":35},{"nctId":"NCT04592536","phase":"PHASE1","title":"A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects","status":"COMPLETED","sponsor":"Cerevel Therapeutics, LLC","startDate":"2020-10-06","conditions":"Panic Disorder","enrollment":56},{"nctId":"NCT00635531","phase":"PHASE4","title":"A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-04","conditions":"Panic Disorder","enrollment":16},{"nctId":"NCT00635076","phase":"PHASE4","title":"A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-07","conditions":"Panic Disorder","enrollment":3},{"nctId":"NCT01322867","phase":"PHASE4","title":"A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-05","conditions":"Healthy","enrollment":30},{"nctId":"NCT00634790","phase":"PHASE4","title":"A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-05","conditions":"Panic Disorder","enrollment":49},{"nctId":"NCT00860119","phase":"PHASE1","title":"Bioequivalence of Alprazolam Sublingual vs Oral Tablets","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2009-08","conditions":"Healthy","enrollment":23},{"nctId":"NCT01046162","phase":"PHASE1","title":"A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-07-15","conditions":"Healthy","enrollment":""},{"nctId":"NCT01027689","phase":"PHASE1","title":"Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-04","conditions":"Healthy","enrollment":""},{"nctId":"NCT00810316","phase":"PHASE1","title":"Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-10","conditions":"Pharmacokinetics","enrollment":24},{"nctId":"NCT04658732","phase":"PHASE1","title":"A Comparative Study of Oral Gabapentin, Oral Alprazolam and Intravenous Dexmedetomidine on Perioperative Anxiety and Pain During Posterior Segment Eye Surgery Under Peribulbar Block : a Randomized, Double-blind Study.","status":"UNKNOWN","sponsor":"Ehab Tarek Fahmy","startDate":"2020-12-01","conditions":"Sedation for Patients Undergoing Peribulbar Block","enrollment":45},{"nctId":"NCT03286218","phase":"PHASE1","title":"A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-09-15","conditions":"Recreational Drug Use, Prescription Drug Abuse (Not Dependent)","enrollment":96},{"nctId":"NCT03012334","phase":"PHASE1","title":"The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-01-16","conditions":"Migraine","enrollment":90},{"nctId":"NCT00603980","phase":"PHASE1","title":"Staccato Alprazolam Abuse Liability","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2008-01","conditions":"Abuse Liability of Staccato Alprazolam","enrollment":31},{"nctId":"NCT00574639","phase":"EARLY_PHASE1","title":"Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":14},{"nctId":"NCT03814733","phase":"PHASE1","title":"Assessment of Effect of Rapastinel on Driving Performance","status":"COMPLETED","sponsor":"Naurex, Inc, an affiliate of Allergan plc","startDate":"2018-11-05","conditions":"Driving Performance","enrollment":107},{"nctId":"NCT03576456","phase":"NA","title":"Sedative Premedication in Coronary Angiography","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2019-01-01","conditions":"Coronary Angiography, Sedative Premedication","enrollment":264},{"nctId":"NCT03447353","phase":"PHASE4","title":"Opiates and Benzodiazepines on Driving","status":"COMPLETED","sponsor":"Timothy L. Brown","startDate":"2016-06-14","conditions":"Driving Behavior","enrollment":18},{"nctId":"NCT03398083","phase":"PHASE1","title":"Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-12-04","conditions":"Cannabis Use Disorder","enrollment":42},{"nctId":"NCT03220113","phase":"PHASE1, PHASE2","title":"Treatment of Chronic Migraine Headaches.","status":"UNKNOWN","sponsor":"Corona Doctors Medical Clinics, Inc.","startDate":"2017-07-01","conditions":"Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders","enrollment":100},{"nctId":"NCT01745575","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 2 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-28","conditions":"Anxiety Disorders","enrollment":26},{"nctId":"NCT01853956","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 0.25 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-02","conditions":"Anxiety Disorders","enrollment":28},{"nctId":"NCT01745562","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 0.5 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-07","conditions":"Anxiety Disorders","enrollment":28},{"nctId":"NCT03130842","phase":"PHASE2, PHASE3","title":"Premedication With Alprazolam and Midazolam for Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2016-09-17","conditions":"Diagnostic Esophagogastroduodenoscopy","enrollment":136},{"nctId":"NCT02570581","phase":"PHASE1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2014-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT00592332","phase":"NA","title":"Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-06","conditions":"Type 1 Diabetes","enrollment":56},{"nctId":"NCT01949038","phase":"PHASE2, PHASE3","title":"Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2011-09","conditions":"Diagnostic Esophagogastroduodenoscopy","enrollment":220},{"nctId":"NCT00139854","phase":"PHASE3","title":"A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-08","conditions":"ANXIETY","enrollment":""},{"nctId":"NCT01898897","phase":"NA","title":"Influence of Anesthesia Technique on Postoperative Evolution After Urogenital Surgical Interventions","status":"UNKNOWN","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2010-03","conditions":"Anesthesia; Reaction, Adverse Effect of Other General Anesthetics, Adverse Anesthesia Outcome","enrollment":60},{"nctId":"NCT00975481","phase":"PHASE1","title":"A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10","conditions":"Alzheimer's Disease, Huntington's Disease","enrollment":36},{"nctId":"NCT01486615","phase":"PHASE4","title":"Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2011-10","conditions":"Anxiety","enrollment":80},{"nctId":"NCT01546090","phase":"PHASE4","title":"Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2011-03","conditions":"Inferior Alveolar Nerve Block Failure","enrollment":60},{"nctId":"NCT01188031","phase":"PHASE1","title":"A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-06","conditions":"Healthy","enrollment":40},{"nctId":"NCT01188057","phase":"PHASE1","title":"A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-07","conditions":"Healthy","enrollment":40},{"nctId":"NCT00878865","phase":"PHASE1","title":"Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2009-04","conditions":"Healthy","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xanax","Xanax XR","Tafil AP, Xanax XR"],"phase":"marketed","status":"active","brandName":"Oral alprazolam","genericName":"Oral alprazolam","companyName":"Isfahan University of Medical Sciences","companyId":"isfahan-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alprazolam enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects. Used for Generalized anxiety disorder, Panic disorder, Anxiety associated with depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}